Conivaptan (CI-1025, YM087), a combined vasopressin V-1A/V-2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients
Publication
, Conference
Smith, WB; Russell, S; Ghali, JK; Painchaud, CA; Selaru, P; Ghazzi, MM; Konstam, MA; Udelson, JE
Published in: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
February 1, 2001
Duke Scholars
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
February 1, 2001
Volume
37
Issue
2
Start / End Page
172A / 173A
Publisher
ELSEVIER SCIENCE INC
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Smith, W. B., Russell, S., Ghali, J. K., Painchaud, C. A., Selaru, P., Ghazzi, M. M., … Udelson, J. E. (2001). Conivaptan (CI-1025, YM087), a combined vasopressin V-1A/V-2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (Vol. 37, pp. 172A-173A). ELSEVIER SCIENCE INC.
Smith, W. B., S. Russell, J. K. Ghali, C. A. Painchaud, P. Selaru, M. M. Ghazzi, M. A. Konstam, and J. E. Udelson. “Conivaptan (CI-1025, YM087), a combined vasopressin V-1A/V-2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients.” In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 37:172A-173A. ELSEVIER SCIENCE INC, 2001.
Smith WB, Russell S, Ghali JK, Painchaud CA, Selaru P, Ghazzi MM, et al. Conivaptan (CI-1025, YM087), a combined vasopressin V-1A/V-2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 2001. p. 172A-173A.
Smith, W. B., et al. “Conivaptan (CI-1025, YM087), a combined vasopressin V-1A/V-2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 37, no. 2, ELSEVIER SCIENCE INC, 2001, pp. 172A-173A.
Smith WB, Russell S, Ghali JK, Painchaud CA, Selaru P, Ghazzi MM, Konstam MA, Udelson JE. Conivaptan (CI-1025, YM087), a combined vasopressin V-1A/V-2 receptor antagonist, reduces pulmonary capillary wedge pressure independent of baseline serum sodium or vasopressin levels in heart failure patients. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 2001. p. 172A-173A.
Published In
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
ISSN
0735-1097
Publication Date
February 1, 2001
Volume
37
Issue
2
Start / End Page
172A / 173A
Publisher
ELSEVIER SCIENCE INC
Related Subject Headings
- Cardiovascular System & Hematology
- 3201 Cardiovascular medicine and haematology
- 1117 Public Health and Health Services
- 1102 Cardiorespiratory Medicine and Haematology